Overview


Recombinant human endostatin, also known as endostar, is a biotechnologically produced version of a naturally occurring protein called endostatin. Endostatin is a fragment of collagen XVIII, a protein found in the extracellular matrix of blood vessels and various tissues. Endostatin gained significant attention due to its potential anti-angiogenic properties. Angiogenesis is the procedure of forming new blood vessels from pre-existing ones, and it plays a crucial role in different physiological processes, including wound healing and tissue regeneration. However, it is also a critical factor in the growth and spread of tumors, which rely on a steady blood supply for their development.

Recombinant human endostatin is developed through various medical applications, one of which is genetic engineering techniques, where the human endostatin gene is inserted into a host organism, like bacteria or yeast. The host then produces the endostatin protein, which can be harvested and purified for medical use. The potential applications of recombinant human endostatin lie primarily in cancer treatment. By inhibiting angiogenesis, endostatin can potentially starve tumors of their blood supply, hindering their growth and metastasis. However, it's important to note that while preclinical studies and early clinical trials have shown promise, more research is needed to fully understand its effectiveness and safety profile in different types of cancer.

FutureWise Market Research has published a report that provides an insightful analysis recombinant human endostatin market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts recombinant human endostatin market estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Pfizer Inc.
  • Novus Biologicals
  • Biocon
  • Thermo Fisher Scientific
  • Yantai Medgenn Ltd.
  • FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
  • PeproTech, Inc.
  • Onyx Pharmaceuticals, Inc.
  • Genexine, Inc.
  • Hetero.
  • Intas Pharmaceuticals Ltd. 
  • Novartis AG.

(Note: The list of the major players will be updated with the latest market scenario and trends)

The escalating global prevalence of cancer is anticipated to drive the market's growth over the projection period. Recombinant human endostatin is a beacon of hope in this landscape, boasting potent anti-cancer properties. Its unique ability to inhibit angiogenesis, a process in tumor progression, positions it as a promising candidate for cancer intervention. As the demand for effective treatments soars, this innovative therapy is poised for widespread adoption, offering renewed prospects in the battle against this formidable disease. With its potential to revolutionize cancer care, recombinant human endostatin is a compelling driver for improved oncological outcomes. Additionally, the potent anti-angiogenic properties of recombinant human endostatin, which effectively inhibits the formation of new blood vessels, mark it as a highly promising contender in cancer treatment. By disrupting the critical process of angiogenesis, this biopharmaceutical curtails the tumor's ability to establish a robust blood supply, thereby impeding its growth and metastasis.

This unique mechanism of action not only showcases the therapeutic potential of recombinant human endostatin across a spectrum of cancers but also highlights its significance in advancing oncological interventions, offering renewed hope for patients and clinicians, and further accelerating the market expansion. However, the development of biopharmaceuticals, such as recombinant human endostatin, demands substantial financial investment in research and development. This high-cost barrier poses a considerable challenge, especially for smaller companies or institutions with limited resources. The intricate processes involved in creating and testing these advanced therapies, along with the need for compliance with rigorous regulatory standards, further contribute to the financial burden. As a result, many promising innovations may face hurdles in reaching the market, potentially impeding the progress and accessibility of groundbreaking treatments. 

By Application

  • Medical Application
  • Scientific Application

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. This is driven by factors like the increasing prevalence of cancer, demand for effective therapeutic intervention, increasing research and development activities, growing awareness, high healthcare spending, and well-established healthcare infrastructure in the region, which is expected to propel the demand for the recombinant human endostatin market over the forecast period. In addition, favorable government guidelines and initiatives to support cancer research and development is further boosting the market growth. Also, the presence of key market players, product approvals and launches, and collaborations between pharmaceutical companies and research institutions is also anticipated to drive market growth in the area.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Recombinant Human Endostatin Market By Application, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1 Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3.Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Recombinant Human Endostatin Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Recombinant Human Endostatin Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Recombinant Human Endostatin Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Recombinant Human Endostatin Market, By Application Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Medical Application
      2. Scientific Application
         
  • 8.  North America Recombinant Human Endostatin Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 9.  Latin America Recombinant Human Endostatin Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 10.  Europe Recombinant Human Endostatin Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 11.  Asia Pacific Recombinant Human Endostatin Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 12.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 13.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 14.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio,
    •   1. Pfizer Inc.
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Novus Biologicals
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Biocon
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Thermo Fisher Scientific
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Yantai Medgenn Ltd
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. PeproTech, Inc.
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Onyx Pharmaceuticals, Inc.
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Genexine, Inc.
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Hetero
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Intas Pharmaceuticals Ltd.
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Novartis AG
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview

  • 15.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
            administrations
        5. The overall economic slowdown of the developing and developed nations

  • 16.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients